BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 1016973)

  • 1. Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy.
    Bellet RE; Engstrom PF; Catalano RB; Creech RH; Mastrangelo MJ
    Cancer Treat Rep; 1976 Sep; 60(9):1395-7. PubMed ID: 1016973
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase III study of ICRF-159 versus 5-FU in the treatment of advanced metastatic colorectal carcinoma.
    Paul AR; Catalano RB; Engstrom PF
    Cancer Treat Rep; 1980; 64(10-11):1047-9. PubMed ID: 7006805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of ICRF-159 (NSC-129943) in advanced colorectal carcinoma.
    Marciniak TA; Moertel CG; Schutt AJ; Hahn RG; Reitemeier RJ
    Cancer Chemother Rep; 1975; 59(4):761-3. PubMed ID: 1100228
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination chemotherapy for advanced colorectal cancer with triazinate, ICRF-159, 5-FU, and methyl-CCNU.
    Vogl SE; Qazi R; Berenzweig M
    Cancer Treat Rep; 1980; 64(10-11):1143-5. PubMed ID: 7459902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Razoxane, metastasis and adjuvant chemotherapy.
    Hellmann K
    Clin Exp Metastasis; 1987; 5(1):1-2. PubMed ID: 3829493
    [No Abstract]   [Full Text] [Related]  

  • 6. Eastern Cooperative Oncology Group phase II studies in advanced measurable colorectal cancer. I. Razoxane, Yoshi-864, piperazinedione, and lomustine.
    Douglass HO; MacIntyre JM; Kaufman J; Von Hoff D; Engstrom PF; Klaassen D
    Cancer Treat Rep; 1985 May; 69(5):543-5. PubMed ID: 2988774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of razoxane (ICRF-159) in patients with squamous cell carcinoma of the head and neck previously exposed to systemic chemotherapy.
    Shah MK; Engstrom PF; Catalano RB; Paul AR; Bellet RE; Creech RH
    Cancer Treat Rep; 1982 Mar; 66(3):557-8. PubMed ID: 7060043
    [No Abstract]   [Full Text] [Related]  

  • 8. Combination chemotherapy in patients with advanced colorectal carcinoma previously treated with 5-FU.
    Windschitl HE; Krook JE; Everson LK; Cullinan SA; Scott M
    Cancer Treat Rep; 1982 Dec; 66(12):2093-4. PubMed ID: 7139652
    [No Abstract]   [Full Text] [Related]  

  • 9. Adjuvant oral razoxane (ICRF-159) in resectable colorectal cancer.
    Gilbert JM; Hellmann K; Evans M; Cassell PG; Stoodley B; Ellis H; Wastell C
    Cancer Chemother Pharmacol; 1982; 8(3):293-9. PubMed ID: 7127660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy of advanced colorectal cancer with triazinate and ICRF-159 after failure of 5-Fluorouracil.
    Vogl SE; Lanham R; Kaplan BH
    Oncology; 1980; 37(5):314-5. PubMed ID: 7003455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ICRF-159: current status and clinical prospects.
    Bellet RE; Rozencweig M; Von Hoff DD; Penta JS; Wasserman TH; Muggia FM
    Eur J Cancer (1965); 1977 Nov; 13(11):1293-8. PubMed ID: 590286
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II trial of ICRF-187 in squamous cell carcinoma of the head and neck.
    Wheeler RH; Bricker LJ; Natale RB; Baker SR
    Cancer Treat Rep; 1984 Feb; 68(2):427-8. PubMed ID: 6421483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study on oral N-methylformamide in metastatic colorectal cancer.
    Planting AS; Klijn JG; Verweij J; Stoter G
    Cancer Treat Rep; 1987 Dec; 71(12):1293-4. PubMed ID: 3690540
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.
    Windschitl H; Scott M; Schutt A; McCormack G; Everson L; Cullinan S; Gerstner J; Krook J; Laurie J; Shreck R
    Cancer Treat Rep; 1983 Nov; 67(11):1001-8. PubMed ID: 6640551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of esorubicin in patients with advanced colorectal carcinoma and no prior chemotherapy: an Illinois Cancer Council Trial.
    Locker GY; Hoeltgen T; Kilton L; Krauss S; McNamara M; Blough R; Johnson C
    Cancer Treat Rep; 1987; 71(7-8):765-6. PubMed ID: 3300969
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II study of ICRF-159 in non-Hodgkin's lymphomas.
    Flannery EP; Corder MP; Sheehan WW; Pajak TF; Bateman JR
    Cancer Treat Rep; 1978 Mar; 62(3):465-7. PubMed ID: 348318
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II evaluation of metoprine with leucovorin rescue in patients with advanced colorectal carcinoma.
    Lynch G; Currie V; Kemeny N
    Cancer Clin Trials; 1981; 4(3):281-3. PubMed ID: 6974612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of aminothiadiazole in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial.
    Locker GY; Khandekar J; Krauss S; Reisel H; Hoeltgen T; Wolter J; Haid M; Hoffman R; Blough R; Johnson C
    Cancer Treat Rep; 1987 Jun; 71(6):649-50. PubMed ID: 3555791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of experimental colorectal cancer by razoxane (ICRF-159).
    Gilbert JM; Thompson EM; Slavin G; Kark AE
    Br J Surg; 1984 Aug; 71(8):600-3. PubMed ID: 6743979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of metastatic colorectal carcinoma with cisplatin and 5-FU.
    Shepard KV; Faintuch J; Bitran JD; Sweet DL; Robin E; Levin B
    Cancer Treat Rep; 1985 Jan; 69(1):123-4. PubMed ID: 4038471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.